Journal article
Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight
- Abstract:
- We present a review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The analysis of ethical considerations is contextualised in an overview of the evidence for ketamine use in depression, and a review of the drug's safety profile. We find that, based on current evidence, ketamine use for severe, treatment-resistant depression does not violate ethical principles; however, clinicians and professional bodies must take steps to ensure that guidelines for good practice are enacted, that all experimental and trial data are made available through national registries, and that the risk potential of ketamine treatment continues to be monitored and modelled. We conclude with a set of key recommendations for oversight bodies that would support safe, effective, and ethical use of ketamine in depression.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 356.3KB, Terms of use)
-
- Publisher copy:
- 10.1016/S2215-0366(17)30102-5
Authors
- Publisher:
- Elsevier
- Journal:
- Lancet Psychiatry More from this journal
- Volume:
- 4
- Issue:
- 5
- Pages:
- 419-426
- Publication date:
- 2017-04-05
- Acceptance date:
- 2016-11-16
- DOI:
- EISSN:
-
2215-0374
- ISSN:
-
2215-0366
- Pubs id:
-
pubs:665769
- UUID:
-
uuid:1e2b2fc7-1a07-465f-af49-830ec98f2825
- Local pid:
-
pubs:665769
- Source identifiers:
-
665769
- Deposit date:
-
2016-12-14
Terms of use
- Copyright holder:
- © 2017 Elsevier Ltd
- Copyright date:
- 2017
- Notes:
- This is the author accepted manuscript following peer review version of the article. The final version is available online from Elsevier at: 10.1016/S2215-0366(17)30102-5
If you are the owner of this record, you can report an update to it here: Report update to this record